Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed and dated~* Age \> 45 years~* Class I-III OA of the knee and subject meets American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee~Exclusion Criteria:~* Skin lesions or dermatological diseases in the treatment area~* Directly or indirectly involved in the conduct and administration of this study~* Received any investigational medicinal product within 30 days prior to Screening Visit or participation in any previous clinical study with Diractin®~* Pregnancy or lactation~* Residents of psychiatric wards, prisons or other state institutions~* Malignancy within the past 2 years~* Depressive disorders requiring treatment with tricyclics, treatment with other antidepressants must be stable for 3 months prior to screening and throughout the study~* Epilepsy~* Schizophrenia~* Neuropathic pain and any other pain condition requiring chronic use of pain medication~* Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen, celecoxib, sulfonamides and ingredients used in pharmaceutical products including galactose~* Peripheral arterial disease and/or cerebrovascular disease~* History of stroke or myocardial infarction~* Congestive Heart failure NYHA Class II-IV~* History of pancreatitis or peptic ulcers;~* Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)~* Serum creatinine levels \> 2.5 milligrams/deciliter (mg/dL)~* ALT or AST levels ≥ 5 times the ULN~* Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs approved or used for the treatment of pain for the duration of the study

- Gender: ALL
- Minimum Age: 46 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).